Verdict: Side-by-side breakdown using the Bull Rankings model. ETON scored 66.7, AZN scored 72.0 — AZN leads.
Compare another set
Different reporting periods. ETON's fundamentals are as of June 2026, but AZN's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
ETON
Eton Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Quality-Growth
66.7
$55.21 · $1.6B
fundamentals as of
Score gap
5.3
AZN leads
AZN
AstraZeneca PLC
Drug Manufacturers - General · Quality-Growth
72
$159.20 · $246.9B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
Fastest growthETON+104.9%
Strongest balance sheetETON0.63
Highest qualityAZN78 / 100
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
ETON
stronger →← stronger
AZN
58
Qualityreturns · margins · balance sheet
78
98
Growthrevenue & earnings expansion
78
52
Valuevaluation vs sector peers
61
AZN is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ETON
AZN
-$268kF
FCF
$11.8bA-
+104.9%A
Rev
+8.6%B
0.63C+
D/E
0.64C+
14.9xC
P/S
—
1.64C+
PEG
1.12B+
—
P/E
23.8xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ETON
AZN
—
Price vs fair valuelower is cheaper
11% above
—
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~12%/yr
—
1-yr DCF upside
-22%
—
5-yr DCF upside
-10%
—
10-yr DCF upside
+10%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Drug Manufacturers - Specialty & Generic · market cap $1.6b. 17% off the 52-week high of $66.37. Revenue growing +105% — in hypergrowth territory. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $71.00 (implying +29% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 36% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$268k) — capital raises or debt issuance likely required; dilution / leverage risk. Trailing P/E 138.0x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. P/S 14.9x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
AZNAstraZeneca PLC
Drug Manufacturers - General · $159.20 · beta 0.21
Why now
Drug Manufacturers - General · market cap $246.9b. Down 25% from 52-week high of $212.71 — deep drawdown territory. 12 sell-side analysts rate this a Buy with a mean 1-yr target of $206.91 (implying +30% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 21% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ETON and AZN diverge
On the headline score the gap is 5.3 points in favor of AZN. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
QualityETON 58.2 · AZN 77.8AZN +19.6
GrowthETON 98.0 · AZN 78.5ETON +19.5
ValueETON 52.1 · AZN 61.1AZN +9.0
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is AZN or ETON the better stock?
AZN scores higher: AZN 72.0, ETON 66.7 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do AZN and ETON differ most?
The widest gap is quality, where AZN leads by 20 points on the 0–100 pillar scale. Neither name sweeps: they trade the lead across the three pillars, so the comparison is a trade-off rather than one being better on every measure.
How are AZN and ETON scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.